New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation

Fermín Sánchez de Medina1, Abdelali Daddaoua2, Pilar Requena3, Fermín Capitán-Cañadas3, Antonio Zarzuelo1, María Dolores Suárez3 and Olga Martínez-Augustin3*

1Department of Pharmacology, School of Pharmacy, University of Granada, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Granada 18071, Spain
2Department of Environmental Protection, Consejo Superior de Investigaciones Científicas, Estación Experimental del Zaidín, C/Profesor Albareda 1, Granada 18008, Spain
3Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Granada 18071, Spain

Bioactive peptides have proven to be active in several conditions, including inflammatory bowel disease (IBD). This is a chronic and relapsing condition of unknown aetiology that comprises chiefly ulcerative colitis and Crohn’s disease. Although there are treatments for IBD, they have frequent side effects and they are not always effective; therefore there is a need for new therapies that could alleviate this condition. Two bioactive peptides present in milk (transforming growth factor-β (TGF-β) and casein macropeptide, also named glycomacropeptide) have been shown to have intestinal anti-inflammatory activities. In fact, TGF-β is currently added to formulas intended for patients with IBD, and several studies indicate that these formulas could induce clinical remission. In this paper, evidence supporting the anti-inflammatory effect of TGF-β and bovine glycomacropeptide, as well as their mechanisms of action, is reviewed, focusing on the evidence obtained in animal models.

Milk: Biopeptides: Inflammatory bowel disease: Bovine glycomacropeptides: Transforming growth factor-β

Food bioactive peptides

There is a series of specific food peptides referred to as bioactive peptides that, besides their nutritional value, modulate biological processes. Bioactive peptides can be present in food as such or can result from in vivo or in vitro protein digestion. To obtain the latter, proteolytic enzymes from animal or bacterial origin can be used. Many of the bioactive peptide enriched functional foods currently marketed are obtained by bacterial fermentation. The low cost of these products and the positive image associated with fermented drinks and foods make them very attractive. Any source of food proteins can produce bioactive peptides. Thus, they have been isolated from sardine, corn, soya, egg, gelatin, etc. Nevertheless, the main source of food bioactive peptides is milk. Several studies have demonstrated that food bioactive peptides can reach the intestine, resisting digestion, and go through the intestinal barrier, and hence exert effects both at the intestinal and systemic levels. Accordingly, intestinal, cardiovascular and immunological effects have been

Abbreviations: IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; Th, T helper; IFN, interferon; TGF, transforming growth factor; BGMP, bovine glycomacropeptide; TNBS, trinitrobenzene sulfonic acid; DSS, dextran sodium sulphate.

*Corresponding author: Olga Martínez-Augustin, fax +34-958 248960, email omartine@ugr.es
described\(^{(1,3,8)}\). In addition, a group of peptides can also act as biocarriers for Ca and other minerals, increasing their bioavailability\(^{(8,9)}\). The activities of milk peptides and products containing them have been recently reviewed\(^{(1)}\).

**Inflammatory bowel disease**

Inflammatory bowel disease (IBD) is a chronic and relapsing condition that severely affects the quality of life of patients. The term IBD refers to a group of diseases such as microscopic colitis, collagenous colitis, pseudomembranous colitis, ulcerative colitis (UC) and Crohn’s disease (CD). UC and CD are the most relevant conditions, both in incidence and prevalence\(^{(10)}\). They share histological and clinical similarities, but there are clear differences between them; whereas in UC only the colonic mucosa is damaged, in CD any part of the gastrointestinal tract from the mouth to the anus can be affected (although mostly the ileum and colon), and damage involves not only the intestinal mucosa but the whole intestinal wall\(^{(10)}\). On the other hand, differences in the pathophysiology of these diseases have been observed that indicate a preponderance of T helper (Th) 1 response in CD patients, with an increased production of IL-12, interferon (IFN)-\(\gamma\) and IL-18, whereas a Th2 response seems to be operating in UC patients\(^{(11)}\).

The aetiology of IBD is unknown but an interplay of genetic\(^{(12)}\) and environmental factors (dietary habits, smoking and stress) has been associated with this condition\(^{(10,13–15)}\). Genetic variants have been linked to intestinal microflora and intestinal permeability alterations in IBD patients, and currently the most accepted theory proposes that intestinal inflammation results from an inappropriate immune response by the host (driven by genetic and environmental factors) to the intestinal microflora.

IBD can be currently treated with drugs, among which immunosuppressors, like azathioprine and corticoids, and aminosalicylates, together with anti-TNF antibodies, are the treatment of choice in acute episodes and/or for delaying relapses of the disease\(^{(10)}\). Unfortunately, most of these treatments can lead to severe side effects\(^{(16)}\). Therefore, the search for new treatments that could alleviate or treat the disease is in progress.

**Pathophysiology of inflammatory bowel disease**

Every type of intestinal cell is involved in the pathophysiology of IBD. Epithelial cells constitute the first line of defence. Studies in which the NF-\(\kappa\)B response in the intestinal epithelium of mice was specifically ablated showed that colonic inflammation and pancolitis developed at 3 weeks of age\(^{(17)}\). The authors of this study indicated that the inhibition of the NF-\(\kappa\)B response favours the disruption of the intestinal barrier integrity, resulting in bacterial translocation and intestinal inflammation\(^{(17)}\). In accordance with this observation, low levels of defensins in intestinal epithelial cells have been observed in IBD patients\(^{(18)}\).

Macrophages and neutrophils are the first cells attracted to the focus of inflammation. There macrophages produce mainly TNF, IL-1\(\beta\), IL-6 and IL-12. These cytokines attract neutrophils, T and B lymphocytes and regulate the inflammatory response. At least four different types of CD4\(^{+}\) Th lymphocytes (Th1, Th2, Th17 and Treg) are involved in the immune response in IBD. These are the result of naive Th cell (Th0) differentiation that ultimately depends on the cytokines produced in the inflammatory site (Fig. 1). Differentiated Th cells in turn produce cytokines that regulate the immune response activating or directing B lymphocytes, macrophages, neutrophils and cytotoxic cells.

Treg are CD4\(^{+}\)Foxp3\(^{+}\) regulatory T cells that play an essential role in intestinal homoeostasis. Treg are characterized by the expression of Foxp3, which is considered to confer their regulatory activity\(^{(19)}\). The expression of Foxp3 in peripheral Th0 is dependent on transforming growth factor (TGF)-\(\beta\). Treg appear in the intestine after the oral administration of antigens and produce IL-10 and TGF-\(\beta\)-1, which, in general terms, down-regulate inflammation. Several pro-inflammatory cytokines inhibit Treg induction, including IL-6, IL-21, IL-23 and IL-27. Among them, IL-23 is the key for the inhibition of Treg during inflammation\(^{(20)}\). IBD patients appear to have lower numbers of Treg both in blood and colon; nevertheless it is important to bear in mind that Treg isolated from these patients are functionally active *in vitro*\(^{(20)}\).

Th17 cells are a newly described subpopulation of Th cells involved in the pathogenesis of IBD. These pro-inflammatory lymphocytes are characterized by the expression of the master transcription factor retinoic acid-related orphan receptor-\(\gamma\) as well as IL-17A, IL-17F, IL-21, IL-22 and IL-26\(^{(21)}\). Th17 cells differentiate under the influence of IL-1\(\beta\), IL-6, IL-21, IL-23 and TGF-\(\beta\). The latter has been shown to be essential for differentiation\(^{(21)}\). Th17 cells appear to be involved in the pathophysiology of IBD, particularly in CD, in which Th1 cells are also implicated\(^{(22–24)}\).

Th1 cells express STAT-4 and produce IL-2, IL-12, IL-18 and IFN-\(\gamma\). While IFN-\(\gamma\), IL-12 and IL-18 drive Th1 differentiation, IL-10, TGF-\(\beta\) and IL-4 inhibit it. IL-2...
acting in an autocrine fashion induces Th1 proliferation. The Th1 response implicates mainly the activation of macrophages, increasing the production of IFN-γ by lymphocytes and in turn the production of IL-12 by macrophages and dendritic cells. Th2 cells express GATA-3 and produce IL-4, IL-5, IL-6 and IL-13, Th2 cells proliferate in response to IL-4, while IFN-γ inhibits them. The activation of the Th2 response implicates B cells, increasing antibody production. As indicated above, the Th1 response is predominant in CD patients, while in UC colitis the Th2 response seems to dominate (10).

Animal models of inflammatory bowel disease

In general, animals do not suffer from chronic intestinal inflammation spontaneously. Therefore, several animal models that mimic different aspects of the disease have been developed, including gene knockout, transgenic, chemical and adoptive transfer models (25). Chemical manipulations that are not found in human IBD (31).

The most used knockout model of IBD is the Il10−/− mice. These animals develop a spontaneous caecal inflammation and colitis at 2–4 months of age that features many characteristics observed in human IBD. The inflammation in this model is Th1 driven and is similar, therefore, to CD inflammation in human subjects. Transgenic models of IBD are well represented by the HLA-B27 model of rat colitis. In this model human HLA-B27/microglobulin 2 transgenic rats develop chronic colitis that, among other characteristics, is accompanied by some extraintestinal complications resembling those seen in IBD patients, like spondyloarthropathy involving peripheral and axial joints, dermatological complications and male genital inflammation (32). Finally, in the transfusion model CD4+ CD45RBhigh T cells (or equivalent) from healthy wild-type mice are transferred to mice lacking functional B and T cells (33). After 5–8 weeks, pancolitis and intestinal inflammation are observed in recipient mice with features that are similar to those of human CD. This model presents the advantages that both early symptoms of inflammation and the perpetuation of the disease can be studied (33).

Bioactive peptides and inflammatory bowel disease

So far, the evidence indicates that at least two milk bioactive peptides could be useful in the treatment of IBD: TGF-β and bovine glycomacropetide (BGMP), also known as bovine casein macropetide.

TGF-β is a growth factor present in high concentrations in the milk of several species, including human milk, and it is also produced in small amounts in the intestine of newborn infants. There are at least three isoforms of TGF-β (TGF-β1, TGF-β2 and TGF-β3). These isoforms have high homology among themselves (70% TGF-β1 v. TGF-β2 and 74% TGF-β3 v. TGF-β2), and the amino acid sequence is also highly conserved in different species (<94%) (34). It has been described that TGF-β1 and TGF-β2 are generally equivalent in their functionality both in vivo and in vitro (35). Human milk contains mainly TGF-β1 and TGF-β2, the last being the major isoform (95%) (34, 36). Recent studies indicate that TGF-β is expressed as a pre-pro-factor that gives rise to the secretion of the pro-factor after intracellular hydrolysis, included with other proteins in a latent complex. The latent form in milk is finally activated by gastric acid (37).

TGF-β has pleiotropic functions, including the regulation of the immune function as well as functions related to cellular growth and differentiation. TGF-β1 transferred from the mother via placenta or milk is so biologically relevant that mice in which this gene is disrupted survive until weaning and then succumb to a wasting syndrome accompanied by a multifocal, mixed inflammatory cell response and tissue necrosis, leading to organ failure and death (38). It has been widely demonstrated in rodents that the oral administration of TGF-β induces oral tolerance and inhibits allergic reactions (35). When TGF-β is orally administered to TGF-β-null mice it prevents their death and can be localized in internal organs such as the lung, indicating that it can be active at extraintestinal levels (39, 30). The fast absorption in newborns together with
the detection of high TGF-β levels in the plasma of healthy human volunteers reinforces this hypothesis\(^{(35,40)}\).

Alterations in TGF-β signalling can play an important role in IBD. In fact, in a study carried out in mice in which a dominant-negative mutant form of the TGF-β type II receptor was overexpressed specifically in the intestine, the animals spontaneously developed diarrhea and under specific pathogen-free conditions they were more susceptible to the induction of colonic inflammation by DSS\(^{(41)}\). In these mice, treatment with DSS produced an increased expression of MHC class II, an exacerbated generation of autoantibodies against intestinal goblet cells, and an augmented activity of matrix metalloproteinase in intestinal epithelial cells, compared with wild-type littermates\(^{(41)}\). On the other hand, there is strong evidence that indicates the importance of TGF-β in the development of IBD. The induction of TGF-β brought about by the oral administration of haptenated colonic proteins (to induce oral tolerance) protects mice from the induction of colitis by the administration of TNBS\(^{(3)}\). This preventive effect is also obtained after the systemic administration of TGF-β. Conversely, the administration of anti-TGF-β antibodies reverses the protective effect of oral haptenated colonic proteins\(^{(42)}\). These studies indicate that TGF-β is a major regulator of intestinal mucosal homeostasis, acting in fact by regulating suppressive cells in an autocrine fashion, preventing the expression of IFN-γ and therefore inhibiting the activation of T (mainly Th1) and B cells, resulting in protection of the epithelial monolayer from the permeability-enhancing effects of TNF-β\(^{(40)}\).

Several authors have shown that the oral administration of TGF-β has anti-inflammatory effects at the intestinal level in animal models of colitis. Recently, a study has been published in which animals were fed cow’s milk (500 µl) containing TGF-β (3 µg/l) daily for 2 weeks, before the induction of colitis by the administration of DSS. The authors observed that the animals that received TGF-β lost less weight and had a decreased degree of intestinal inflammation\(^{(35)}\). Furthermore, in 2005 Schiffrin et al. carried out a study to determine the effect of a casein-based formula containing TGF-β (1 ng/mg protein) to treat inflammation in human leucocyte antigen (HLA)-B27 transgenic rats\(^{(16)}\). These authors described that the administration of TGF-β reduced leukocytes and the acute phase reactants fibrinogen and orosomucoid. In addition, colonic weight and wall thickness as well as the mRNA for IFN-γ were reduced. Finally, there was an increase in mucin-2 production in the caecum of the animals that received the TGF-β containing formula and a normalization of the muscle proteolytic activity. A formula with the same protein composition has been proven to be anti-inflammatory in paediatric patients with CD, associated with a reduction in the expression of IFN-γ\(^{(43)}\). In this study, seven children with CD received a TGF-β2-enriched formula for 8 weeks. In spite of the small number of patients, the results were quite clear since all the children showed a significant improvement of the disease activity, with C-reactive protein returning to normal, an increase in serum albumin and a substantial weight gain. Furthermore, ileal biopsies of these children showed reduced mucosal inflammation in six of seven children, with complete healing in two\(^{(43)}\). However, the lack of a control group limits the usefulness of this study. This was followed by another study with 29 children with CD in which a 79% remission rate was achieved, with complete healing in ten cases, after 8 weeks administration of the TGF-β-enriched formula\(^{(44)}\). In this study, Fell et al. described a fall in ileal IFN-γ, indicating a decrease in Th1 response, and a strong fall in ileal and colonic IL-1β and in colonic IL-8 mRNA\(^{(44)}\).

These and several other studies have indicated that formulas enriched in TGF-β could induce clinical remission associated with mucosal healing in IBD patients\(^{(43–46)}\). These formulas are casein-based, lactose-free formulas that are enriched in TGF-β and are currently in the market. Although several studies have shown that the formulas are less effective than corticosteroids, they have proven to be more active in paediatric patients than in adults\(^{(45)}\). As a result, TGF-β-enriched formulas are used in paediatric patients in which the administration of corticosteroids could have deleterious effects on linear growth\(^{(45)}\).

The other bioactive peptide potentially useful in IBD is BGMP, a 64-amino-acid peptide derived from the digestion of milk k-casein. This peptide is produced physiologically in vivo, as a result of k-casein hydrolysis, and in vitro. Actually, BGMP is one of the components that elute with the whey that results after chymosin digestion during the cheese-making process. This peptide can be easily purified and is found in the market with a high degree of purity. BGMP is heavily glycosylated and many of its actions depend on glycosylation\(^{(47)}\).

A wide variety of actions and applications have been described for BGMP. Because it does not contain phenylalanine in its sequence, BGMP has been proposed to be useful in the making of products for individuals with phenylketonuria\(^{(48–50)}\). On the other hand, this peptide has anticarcinogenic properties and has been proposed to be used in tooth pastes\(^{(47)}\). Its mechanism of action is related to the inhibition of bacterial growth, the prevention of tooth demineralization and the promotion of enamel remineralization\(^{(47)}\). In addition, BGMP may combat infection since it has been reported to bind to cholera and Escherichia coli enterotoxins, to inhibit bacterial and viral adhesion, to promote bifidobacteria growth and to modulate the immune system response\(^{(2,6,7)}\). Because of its facilitation of mineral absorption\(^{(51)}\) and its possible antimicrobial and prebiotic effects, BGMP is added to infant formulas\(^{(52)}\). It is important to indicate that, although as indicated earlier there are some studies showing that this peptide promotes the growth of bifidobacteria in vitro\(^{(53,54)}\), so far there is not definitive evidence of the prebiotic effect of BGMP, since the studies carried out with rhesus monkeys and human infants were hampered by a high initial level of bifidobacteria\(^{(51,55)}\).

BGMP has been shown to affect both innate and adaptive immunity. Thus BGMP increases the proliferation of concanavalin A-stimulated rat splenocytes\(^{(36)}\) and induces the expression and production of inducible nitric oxide synthase, cyclooxygenase, IL-10 and Foxp3 at the concentration of 1 g/l. However, there is also evidence that BGMP inhibits mouse splenocyte proliferation induced by lipopolysaccharide and phytohaemagglutinin\(^{(57)}\), while an
inhibition in the production of IFN-γ has been observed in concanavalin A-stimulated splenocytes (P Requena, A Daddaoua, A Zarzuelo, MD Suárez, F Sanchez de Medina and O Martinez-Augustin, unpublished results).

In macrophages BGMP seems to have also a stimulatory effect. For instance, BGMP increased the proliferation and phagocytic activity in a human macrophage cell line\(^{(58)}\). Our research group has shown, both in THP-1 cells (a monocyte/macrophage cell line) and in human peripheral blood macrophages, that BGMP stimulates the production of several cytokines (TNF, IL-1β and IL-8)\(^{(59)}\). In these experiments the mechanism of action of this peptide was further studied, showing that the whole peptide is needed, since it was active when protease inhibitors were added to the culture medium\(^{(59)}\), and no effect was observed when it was hydrolysed (P Requena, A Daddaoua, A Zarzuelo, MD Suárez, F Sanchez de Medina and O Martinez-Augustin, unpublished results). The effect of BGMP was prevented by the addition of mitogen-activated protein kinase or NF-κB inhibitors, and BGMP induced the phosphorylation of NFκB inhibitor-α. Therefore, an involvement of these signal transduction pathways in the stimulatory effect of BGMP on cytokine production by macrophages was hypothesized\(^{(59)}\). In addition, studies by Monnai and Otani\(^{(60)}\) indicated that BGMP increases the expression of an IL-1 receptor antagonist-like component in mouse spleen cells, involving probably monocytes.

In general, these results suggest that BGMP modulates the immune/inflammatory response by the activation of macrophages, favouring the differentiation of Treg cells and hampering the activation of Th1 cells.

As stated above, an exacerbated immune response and an imbalance in the intestinal flora have been blamed, among other factors, for the aetiology of IBD. The fact that BGMP exerts immunomodulatory, antimicrobial and possibly probiotic activities makes it a very good candidate to modulate intestinal inflammation. In fact, our research group has described that the oral administration of BGMP results in substantial anti-inflammatory effects in experimental colitis and ileitis\(^{(30,61)}\).

In a first study we used the model of colitis induced by the administration of TNBS to rats. The animals were administered BGMP daily starting either 2 d before (pre-treatment) or 3 h after (post-treatment) colitis induction\(^{(61)}\). The effect of BGMP (500 mg/kg per d) was compared with that of sulfasalazine, an established drug used in the treatment of IBD. We found that pre-treatment with glycomacropeptide had a dose-dependent anti-inflammatory effect, characterized by lower body-weight loss, decreased anorexia (57%), colonic damage (65%) and weight; length ratio (32%), as well as a reduction in colonic alkaline phosphatase activity (42%) and IL-1β, trefoil factor 3 and inducible nitric oxide synthase mRNA levels (\(P<0.05\))\(^{(61)}\). The magnitude of the anti-inflammatory effect was generally comparable with that of sulfasalazine\(^{(61)}\).

To further ascertain the mechanism involved in the anti-inflammatory effect of BGMP and to find new beneficial applications for this peptide, we studied its effect in a model of ileitis induced by the injection of TNBS in the ileum of rats\(^{(30)}\). Since CD affects any part of the intestine, ileitis frequently affects CD patients. Furthermore, ileitis can be also the result of ileal infections\(^{(62,63)}\) and it is a frequent complication of the ileal pouch-anal anastomosis interventions practised to treat UC\(^{(64)}\). While lymphocyte Th1 and Th2 responses are predominant in colonic CD and UC patients, respectively, it seems that at least in Crohn’s ileitis both types of T cells are involved in the inflammatory response. Our results indicated that BGMP pre-treatment (500 mg/kg per d) results in a marked reduction of inflammatory injury, as assessed by lower extension of necrosis and diminished damage score, myeloperoxidase, alkaline phosphatase, inducible nitric oxide synthase, IL-1β and IL-17. Again, the effects of BGMP were similar to those observed in the same experiment for 5-aminosalicylic acid (200 mg/kg per d). 5-Aminosalicylic acid is the active part of sulfasalazine, which is released from the produg by colonic bacteria\(^{(65)}\).

From the above-mentioned studies with BGMP, we can conclude that BGMP has an anti-inflammatory effect in animal models of ileitis and colitis induced by TNBS and that this effect is comparable with that of drugs frequently used to treat IBD. We have shown that BGMP decreases the expression of IL-1β, IL-1ra, TNF and IL-17 in ileitis/colitis and therefore we can conclude that the mechanism of action of BGMP probably involves Th17 cells, macrophages and T cells but not Th1 cells\(^{(30,61)}\).

In a third study, we obtained mRNA from the colon of control and TNBS colitic rats administered vehicle or BGMP (500 mg/kg per d) as described earlier and carried out microarrays, allowing the simultaneous measurement of over 30 000 genes and real-time PCR for 96 selected genes (P Requena, A Daddaoua, A Zarzuelo, MD Suárez, F Sanchez de Medina and O Martinez-Augustin, unpublished results). The use of powerful genomic and post-genomic techniques gave us further insight into the mechanism of action of this peptide. The processing of our results from microarrays and real-time PCR with Ingenuity Pathway Analysis software indicated that the Il1b (IL-1β) and Il6 (IL-6) genes, both of which are down-regulated by BGMP, are key points in its mechanism of action. We observed also a decrease in Il-17, in neutrophil and macrophage infiltration and in tissue remodelling genes, as well as an increase in the II10 gene and in a set of genes related to lymphocyte infiltration.

IL-6 is a key factor in the development of inflammation and specifically in the uncontrolled inflammatory process in IBD\(^{(66–68)}\). In fact, increased blood and mucosal levels of this cytokine have been described in UC and CD patients, correlated with the severity of the disease\(^{(66)}\). Accordingly, antibodies against IL-6 or its soluble receptor have been shown to be useful in the treatment of IBD in human subjects\(^{(67)}\). There is growing evidence indicating that this cytokine, produced mainly by macrophages and CD4+ T cells, is one of the main ones in the chronic phase of colitis\(^{(66)}\). IL-6 has three main roles in inflammation: (i) the recruitment of neutrophils to the inflammatory site and their activation to produce matrix metalloproteinases, thus contributing to severe tissue damage; (ii) the regulation of CD4+ leucocyte apoptosis; IL-6, together with IL-12 and TNF, is an important anti-apoptotic cytokine involved in the pathogenesis of CD, whose inflammatory response, like that of the TNBS model
of colitis, is driven by Th1 (and possibly Th17) cells; and (iii) the induction of Th17 cell differentiation\(^{66-68}\).

From our results we may hypothesize that down-regulation of Il6 gene expression could: (1) specifically decrease Th17 cell populations, (2) reduce neutrophil infiltration at the site of inflammation, (3) lower the expression of tissue remodelation genes, probably as a consequence of the decreased neutrophil infiltration, and (4) probably allow the expression of Il10, which could also contribute to the resolution of colitis. In this study, control rats were fed with BGMP and Il6 gene expression was also down-regulated in these rats, reinforcing the idea that IL-6 down-regulation could be a key point in the anti-inflammatory effect of BGMP.

It is known that in acute inflammation, leucocyte recruitment to the site of inflammation is characterized by an initial infiltration of neutrophils, which are later replaced by a more sustained influx of mononuclear cells, initially macrophages and then lymphocytes\(^{15}\). Therefore, the presence of increased amounts of lymphocytes together with a decrease in neutrophils and macrophages may be interpreted as indicative of an advanced stage of recovery from inflammation. Our results show just that, i.e. a decrease in the expression of genes related to macrophage and granulocyte activation, movement, recruitment and/or accumulation, with BGMP treatment, together with an up-regulation in both B and T cell marker genes, indicating that the inflammatory state of BGMP-treated animals was closer to resolution (P Requena, A Daddaoua, A Zarzuelo, MD Suárez, F Sanchez de Medina and O Martinez-Augustin, unpublished results). These data are further sustained by the finding that Il1b (mainly produced by macrophages)\(^{59}\) and Il6 (a neutrophil recruitment cytokine)\(^{18}\) are key genes in the effect of BGMP, as indicated by the analysis of microarray data using Ingenuity Pathway Analysis software.

Because of the nature of our studies we cannot ascertain whether BGMP prevents the inflammatory damage induced by TNBS administration or accelerates the recovery from injury. Nevertheless, when BGMP was administered to TNBS rats before (pre-treatment) or after (post-treatment) the TNBS challenge, we found that the pre-treatment was more effective, stressing the importance of preventive actions. As alluded to earlier, studies carried out with splenocytes have shown that the addition of BGMP to culture medium increases the production of macrophage-produced cytokines (IL-1\(\beta\), TNF and IL-8) in a fashion that seems to be dependent on the activation of mitogen-activated protein kinase and NF-κB\(^{59}\). These results are apparently at odds with the anti-inflammatory effect of BGMP. However, the very complexity of IBD pathology makes it possible that monocyte activation may be involved in the anti-inflammatory activity of BGMP. Thus several studies suggest that defective response of the mucosa to harmful stimuli may actually worsen the outcome, at least in some cases\(^{17,69}\). We have already described the study of Nenci et al.\(^{17}\) in which reduced epithelial activation of the NF-κB pathway results in spontaneous severe colonic inflammation. Similarly, the absence of monocytes and dendritic cells aggravates rather than ameliorates experimental colitis\(^{69}\). Because it is well established that intestinal inflammation is strongly dependent on the presence of non-pathogenic bacteria, it may be concluded that the microbiota constitutes the challenge that must be met by the intestinal mucosa in just adequate terms: not too soft, not too hard\(^{70}\). Thus, defects in immune function may impair a prompt resolution of intestinal injury,triggering a more robust reaction to a normally trivial challenge. If so, monocyte stimulation would result in a more efficient and prompt response to luminal antigens as they gain access to the subepithelial milieu. In this regard, it is tempting to speculate that BGMP may work at least in part via monocyte/macrophage-stimulating actions.

**Other biopeptides with anti-inflammatory potential**

As indicated above, a number of milk-derived peptides with antimicrobial and immunomodulatory effects have been described. These properties could be very useful in the amelioration of intestinal inflammation. The properties of these peptides have been discussed in several reviews\(^{1,8}\). Recent studies have shown in the HLA-B27 model of intestinal inflammation that Ca-supplemented diets ameliorate several important aspects of colitis, reducing IL-1\(\beta\) expression and histological scores and increasing the expression of extracellular matrix remodelling genes\(^{71}\). Since many casein phosphopeptides have been shown to enhance Ca\(^{2+}\) absorption in vivo\(^{8,9}\), these could be good anti-inflammatory candidates. On the other hand, several peptides and fermented milk products have been reported to have antioxidant effects. Antioxidants including glutathione and flavonoids\(^{72-75}\) have proven to be effective in the treatment of IBD in several animal models, indicating that perhaps antioxidant peptides derived from milk could also be beneficial.

**Conclusions**

Research is demonstrating that milk-derived peptides offer a wide variety of actions and some of them are good candidates to attenuate intestinal inflammation. Among these peptides TGF-β and BGMP have proven to be useful in animal models of intestinal inflammation and TGF-β has successfully been used in the treatment of CD patients. While TGF-β is a factor involved naturally in intestinal inflammation, its anti-inflammatory mechanism of action, related at least in part to the inhibition of the Th1 response, needs to be better studied. The mechanism of action of BGMP remains to be fully described. Nevertheless, evidence indicates that it could have preventive effects, activating macrophages and, in inflammatory conditions, it could directly or indirectly down-regulate IL-6 and up-regulate IL-10. No clinical studies have been carried out with BGMP although it is known to be a safe food ingredient and is currently being added to infant formulas.

**Acknowledgements**

This work was supported by the ‘Ministerio de Educación y Ciencia’, Spain (grant numbers AGL2008-04332 and SAF2008-01432) and by the Centro de Investigación.
Biomédica en Red de enfermedades Hepáticas y Digestivas (CIBERehd). The authors declare that there are no conflicts of interest. F. S. de M. and O. M.-A. have been chiefly responsible for the writing of this paper and for directing the work that generated the paper of our research group on BGMP. F. C.-C., A. D. and P. R. generated most of the data on BGMP from our research group that have been included in this paper, and have also participated in the writing of the manuscript. A. Z. and M. D. S. have been involved in the discussion of the experimental design and results of the above-mentioned experiments and their treatment in this paper. All the authors have critically reviewed this paper.

References


New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation


71. Schepens MA, Schenonwille AJ, Vink C et al. (2009) Supplementation calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix...


